BAP1 and cutaneous melanoma: Previous studies have demonstrated the robustness and reliability of BAP1 IHC in detecting double hit inactivation/mutation in multiple tumours including uveal melanoma [25,26], cutaneous melanoma [10,21,27], malignant mesothelioma [16,28], and renal cell carcinoma [14].